Advertisement
Screener

BRIACELL THERAPEUTICS CORP. (BCTX) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

2.8 / 5 stars · 68/120 Roast Me

BRIACELL THERAPEUTICS CORP. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

BRIACELL THERAPEUTICS CORP. (BCTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 9-month period ending 2026-04-30, per its 10-Q filed 2026-06-09.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-06-09

  • BRIACELL THERAPEUTICS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-10-31 was 0.00%.
  • BRIACELL THERAPEUTICS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-10-31 was 0.00%.
  • BRIACELL THERAPEUTICS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2022-10-31 was 0.00%.
  • BRIACELL THERAPEUTICS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
  • BRIACELL THERAPEUTICS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
  • BRIACELL THERAPEUTICS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 0 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month
2026-04-300.00%
10-Q · filed 2026-06-09
2026-01-310.00%
10-Q · filed 2026-03-10
2025-10-310.00%
10-Q · filed 2025-12-11
2025-07-310.00%
10-Q · filed 2026-06-09
2025-04-300.00%
10-Q · filed 2025-06-16
2025-01-310.00%
10-Q · filed 2025-03-12
2024-10-310.00%
10-Q · filed 2024-12-16
2024-07-310.00%
10-K · filed 2025-10-16
2023-07-310.00%
10-K · filed 2024-10-29
2023-04-300.00%
10-Q · filed 2023-06-14
2023-01-310.00%
10-Q · filed 2023-03-16
2022-10-310.00%
10-Q · filed 2022-12-14
2022-07-310.00%
10-K · filed 2023-10-25
2021-06-030.00%
10-K · filed 2022-10-28
2021-04-120.00%
10-K · filed 2025-10-16
2021-02-260.00%
10-K · filed 2025-10-16

Similar stocks

Stock NameCountryMarket CapPE Ratio
PMGC Holdings Inc. (ELAB)United States$0.037B
Seres Therapeutics, Inc. (MCRB)United States$0.036B-3.45
FILANA THERAPEUTICS, INC. (FLNA)United States$0.038B-1.05
Actinium Pharmaceuticals, Inc. (ATNM)United States$0.038B2.73
MIRA PHARMACEUTICALS, INC. (MIRA)United States$0.036B-4.30
Celularity Inc (CELU)United States$0.038B-0.34
CervoMed Inc. (CRVO)United States$0.038B-1.39
Edesa Biotech, Inc. (EDSA)Canada$0.039B
ROCKWELL MEDICAL, INC. (RMTI)United States$0.035B
Karyopharm Therapeutics Inc. (KPTI)United States$0.039B-0.98